Home › FDA Approves ZONTIVITY (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
 

Keywords :   


FDA Approves ZONTIVITY (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease

2014-05-12 13:30:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or with history events

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Atlantic Tropical Weather Outlook
28.06Learning to listen to nursery pigs
28.06Incomes have risen 'at a crawl' says think tank
28.06Eastern North Pacific Tropical Weather Outlook
28.06Are rainy days ahead for cloud computing?
28.06Electric car battery charges in under five minutes in track test
28.06Debt relief orders can write off up to 50,000
27.06Strike could force Tata plant to shut next week
More »